Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 9/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23743600 | 0.94 | CTSK (0.40) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL25755539 | 0.92 | CTSK (0.40) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL31510003 | 0.90 | AAK1 (0.49) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL22526025 | 0.86 | CTSK (0.36) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL25315586 | 0.86 | CA1 (0.44) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL13622615 | 0.86 | CA1 (0.44) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL19361663 | 0.86 | CA1 (0.44) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL12265061 | 0.83 | PPARA (0.53) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL22506799 | 0.83 | PPARA (0.53) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL25755528 | 0.83 | PPARA (0.53) | CTSKCTSSCTSLCTSBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605451-B2 | Targeted plasma protein degradation | NOVARTIS AG (CH) | 2026-04-21 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| EP-4100064-A1 | TARGETED PLASMA PROTEIN DEGRADATION | Novartis AG (CH) | 2022-12-14 | — | — | EP | disclosed |
| CN-115335081-A | Targeted plasma protein degradation | 诺华股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2021156792-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605451-B2 | Targeted plasma protein degradation | M6PR, ASGR1, IGF2R | CTSK 516/4885CA1 3916/4885CA2 4235/4885 |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | M6PR, ASGR1, IGF2R | CTSK 701/4885CA1 4351/4885CA2 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.